MBMalte Borggrewe

Malte Borggrewe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Malte Borggrewe has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Bart J. L. Eggen

    Department of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    3 shared publications
  • Corien Grit

    Department of Biomedical Sciences of Cells & Systems Section Molecular Neurobiology, University Medical Center Groningen, University of Groningen Groningen The Netherlands

    2 shared publications
  • Jon D. Laman

    Department of Pathology and Medical Biology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands

    2 shared publications
  • Markus Flosbach

    III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg

    2 shared publications
  • Randolph J. Noelle

    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Lebanon, USA

    2 shared publications
  • Stefan Bonn

    Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications

Latest Publications

  • Open Access

    Seumetry: a versatile and comprehensive R toolkit to accelerate high-dimensional flow and mass cytometry data analysis

    by Malte Borggrewe, Markus Flosbach, Lucia Testa, Cedric Ly, Martin Baumdick, Immo Prinz, Felix J Flomm, Sebastian Schloer, Alaa Akar, Cornelius Flemming, et al.

    Motivation: Recent progress in flow and mass cytometry technologies enables the simultaneous measurement of over 50 parameters for an individual cell. The resulting increase in data volume and complexity present challenges for conventional analysis methods, which are based on manual gating, are time-consuming and fail to capture unknown or minor cell populations. Advances in single-cell RNA sequencing (scRNAseq) technologies have prompted the development of computational analysis tools designed to process and analyze high-dimensional biological data. Building on these advances, we here present Seumetry, a framework that combines flow and mass cytometry data-specific analysis methods with the capabilities of Seurat, a powerful tool for the analysis of scRNAseq data. Results: Seumetry offers methods for advanced quality control, data visualizations, and differential population abundance and protein expression analysis. We tested Seumetry on an in-house generated complex dataset of immune cells from different layers of human intestines, demonstrating that Seumetry accurately identifies distinct immune cell populations. Furthermore, benchmarking against public datasets showed that Seumetry aligns with manual-gated results, further validating its use for high-dimensional flow and mass cytometry data. In summary, Seumetry provides a new scalable framework for the comprehensive analysis of high-dimensional cytometry data with seamless integration into commonly used scRNAseq analysis tools, enabling in-depth analysis methods to facilitate biological interpretations. Availability: Seumetry code is available open source under an MIT license and the current version can be viewed and used via Github: https://github.com/imsb-uke/Seumetry; and archived on Zenodo: https://doi.org/10.5281/zenodo.21216681. Flow cytometry data generated for this manuscript is available via Zenodo: https://doi.org/10.5281/zenodo.11935872.

  • Open Access

    Seumetry: a versatile and comprehensive R toolkit to accelerate high-dimensional flow and mass cytometry data analysis

    by Malte Borggrewe, Markus Flosbach, Hamburg Intestinal Tissue Study Group, Stefan Bonn, Madeleine J. Bunders

    Recent progress in flow and mass cytometry technologies enables the simultaneous measurement of over 50 parameters for an individual cell. The resulting increase in data volume and complexity present challenges, as conventional analysis methods based on manual gating are time-consuming and fail to capture unknown or minor cell populations. Advances in single-cell RNA sequencing (scRNAseq) technologies have prompted the development of sophisticated computational analysis tools specifically designed to process and analyze high-dimensional biological data, some of which could significantly improve certain aspects of cytometry data analysis. Building on these advances, we here present Seumetry, a framework that combines flow and mass cytometry data-specific analysis methods with the capabilities of Seurat, a powerful tool for the analysis of scRNAseq data. Seumetry offers advanced quality control, data visualizations, and differential population abundance and protein expression analysis. We tested Seumetry on an in-house generated complex dataset of immune cells from different layers of human intestines, demonstrating that Seumetry accurately identifies distinct immune cell populations. Furthermore, using a publicly available mass cytometry dataset, Seumetry recapitulates previously published results, further validating its use for high-dimensional flow and mass cytometry data. In summary, Seumetry provides a new scalable framework for the comprehensive analysis of high-dimensional cytometry data with seamless integration into commonly used scRNAseq analysis tools, enabling in-depth analysis methods to facilitate biological interpretations.


  • Open Access

    Tomatidine reduces Chikungunya virus progeny release by controlling viral protein expression

    by Berit Troost-Kind, Martijn J. van Hemert, Denise van de Pol, Heidi van der Ende-Metselaar, Andres Merits, Malte Borggrewe, Izabela A. Rodenhuis-Zybert, Jolanda M. Smit

    Tomatidine, a natural steroidal alkaloid from unripe green tomatoes has been shown to exhibit many health benefits. We recently provided in vitro evidence that tomatidine reduces the infectivity of Dengue virus (DENV) and Chikungunya virus (CHIKV), two medically important arthropod-borne human infections for which no treatment options are available. We observed a potent antiviral effect with EC50 values of 0.82 μM for DENV-2 and 1.3 μM for CHIKV-LR. In this study, we investigated how tomatidine controls CHIKV infectivity. Using mass spectrometry, we identified that tomatidine induces the expression of p62, CD98, metallothionein and thioredoxin-related transmembrane protein 2 in Huh7 cells. The hits p62 and CD98 were validated, yet subsequent analysis revealed that they are not responsible for the observed antiviral effect. In parallel, we sought to identify at which step of the virus replication cycle tomatidine controls virus infectivity. A strong antiviral effect was seen when in vitro transcribed CHIKV RNA was transfected into Huh7 cells treated with tomatidine, thereby excluding a role for tomatidine during CHIKV cell entry. Subsequent determination of the number of intracellular viral RNA copies and viral protein expression levels during natural infection revealed that tomatidine reduces the RNA copy number and viral protein expression levels in infected cells. Once cells are infected, tomatidine is not able to interfere with active RNA replication yet it can reduce viral protein expression. Collectively, the results delineate that tomatidine controls viral protein expression to exert its antiviral activity. Lastly, sequential passaging of CHIKV in presence of tomatidine did not lead to viral resistance. Collectively, these results further emphasize the potential of tomatidine as an antiviral treatment towards CHIKV infection.


  • Open Access

    Regionally diverse astrocyte subtypes and their heterogeneous response to EAE

    by Malte Borggrewe, Corien Grit, Ilia D. Vainchtein, Nieske Brouwer, Evelyn M. Wesseling, Jon D. Laman, Bart J. L. Eggen, Susanne M. Kooistra, Erik W. G. M. Boddeke

    Astrocytes fulfil many functions in the central nervous system (CNS), including contribution to the blood brain barrier, synapse formation, and trophic support. In addition, they can mount an inflammatory response and are heterogeneous in morphology and function. To extensively characterize astrocyte subtypes, we FACS‐isolated and gene expression profiled distinct astrocyte subtypes from three central nervous system regions; forebrain, hindbrain and spinal cord. Astrocyte subpopulations were separated based on GLAST/SLC1A3 and ACSA‐2/ATP1B2 cell surface expression. The local brain environment proved key in establishing different transcriptional programs in astrocyte subtypes. Transcriptional differences between subtypes were also apparent in experimental autoimmune encephalomyelitis (EAE) mice, where these astrocyte subtypes showed distinct responses. While gene expression signatures associated with blood–brain barrier maintenance were lost, signatures involved in neuroinflammation and neurotoxicity were increased in spinal cord astrocytes, especially during acute disease stages. In chronic stages of EAE, this reactive astrocyte signature was slightly decreased, while obtaining a more proliferative profile, which might be relevant for glia scar formation and tissue regeneration. Morphological heterogeneity of astrocytes previously indicated the presence of astrocyte subtypes, and here we show diversity based on transcriptome variation associated with brain regions and differential responsiveness to a neuroinflammatory insult (EAE).


  • Open Access

    Exploring the VISTA of microglia: immune checkpoints in CNS inflammation

    by Malte Borggrewe, Susanne M. Kooistra, Randolph J. Noelle, Bart J. L. Eggen, Jon D. Laman

    Negative checkpoint regulators (NCR) are intensely pursued as targets to modulate the immune response in cancer and autoimmunity. A large variety of NCR is expressed by central nervous system (CNS)-resident cell types and is associated with CNS homeostasis, interactions with peripheral immunity and CNS inflammation and disease. Immunotherapy blocking NCR affects the CNS as patients can develop neurological issues including encephalitis and multiple sclerosis (MS). How these treatments affect the CNS is incompletely understood, since expression and function of NCR in the CNS are only beginning to be unravelled. V-type immunoglobulin-like suppressor of T cell activation (VISTA) is an NCR that is expressed primarily in the haematopoietic system by myeloid and T cells. VISTA regulates T cell quiescence and activation and has a variety of functions in myeloid cells including efferocytosis, cytokine response and chemotaxis. In the CNS, VISTA is predominantly expressed by microglia and macrophages of the CNS. In this review, we summarize the role of NCR in the CNS during health and disease. We highlight expression of VISTA across cell types and CNS diseases and discuss the function of VISTA in microglia and during CNS ageing, inflammation and neurodegeneration. Understanding the role of VISTA and other NCR in the CNS is important considering the adverse effects of immunotherapy on the CNS, and in view of their therapeutic potential in CNS disease.


  • Human fetal microglia acquire homeostatic immune-sensing properties early in development

    by L. Kracht, M. Borggrewe, S. Eskandar, N. Brouwer, S. M. Chuva de Sousa Lopes, J. D. Laman, S. A. Scherjon, J. R. Prins, S. M. Kooistra, B. J. L. Eggen

    The development of microglia: Microglia are the brain's immune cells, and they play important roles in health and neurodegenerative disease. Kracht et al. performed single-cell analysis of human microglial gene expression and chromatin accessibility and compared the results with those of other studies of human and mice microglial development. By using in situ validation, these data identify fetal microglial subsets that appear to be distinct from adult human microglia, suggesting functional differences between the developing and mature brain. Science , this issue p. 530


  • Open Access

    VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases

    by Malte Borggrewe, Corien Grit, Wilfred F. A. Den Dunnen, Saskia M. Burm, Jeffrey J. Bajramovic, Randolph J. Noelle, Bart J. L. Eggen, Jon D. Laman

    V‐type immunoglobulin domain‐containing suppressor of T‐cell activation (VISTA) is a negative checkpoint regulator (NCR) involved in inhibition of T cell‐mediated immunity. Expression changes of other NCRs (PD‐1, PD‐L1/L2, CTLA‐4) during inflammation of the central nervous system (CNS) were previously demonstrated, but VISTA expression in the CNS has not yet been explored. Here, we report that in the human and mouse CNS, VISTA is most abundantly expressed by microglia, and to lower levels by endothelial cells. Upon TLR stimulation, VISTA expression was reduced in primary neonatal mouse and adult rhesus macaque microglia in vitro. In mice, microglial VISTA expression was reduced after lipopolysaccharide (LPS) injection, during experimental autoimmune encephalomyelitis (EAE), and in the accelerated aging Ercc1 Δ/− mouse model. After LPS injection, decreased VISTA expression in mouse microglia was accompanied by decreased acetylation of lysine residue 27 in histone 3 in both its promoter and enhancer region. ATAC‐sequencing indicated a potential regulation of VISTA expression by Pu.1 and Mafb, two transcription factors crucial for microglia function. Finally, our data suggested that VISTA expression was decreased in microglia in multiple sclerosis lesion tissue, whereas it was increased in Alzheimer's disease patients. This study is the first to demonstrate that in the CNS, VISTA is expressed by microglia, and that VISTA is differentially expressed in CNS pathologies.